New Zealand markets closed

PFE Jan 2024 55.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.02000.0000 (0.00%)
As of 09:54AM EDT. Market open.
Full screen
Previous close0.0200
Expiry date2024-01-19
Day's range0.0200 - 0.0200
Contract rangeN/A
Open interestN/A
  • Financial Times

    Reversal of fortunes for Covid-19 vaccine winners

    At the height of the pandemic, investors clamoured to buy vaccine makers, the closest thing to a sure bet. Shares in Pfizer, which developed a vaccine and an antiviral, have plummeted 46 per cent from their peak in late 2021, while its German vaccine partner BioNTech is down 75 per cent and rival Moderna has plunged 79 per cent. Less successful vaccine makers have fallen back even more dramatically: shares in Novavax, which has an approved Covid-19 shot that has sold far fewer than the mRNA jabs, has fallen 97 per cent since early 2021.

  • Motley Fool

    3 Top Stocks to Buy in October and Hold Forever

    Check out these three blue chip buys playing crucial roles in America's $6 trillion healthcare opportunity.

  • Zacks

    Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag

    FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.